IP Verse

Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole - EP3191461

The patent EP3191461 was granted to Pfizer on Nov 3, 2021. The application was originally filed on Aug 31, 2015 under application number EP15771276A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3191461

PFIZER
Application Number
EP15771276A
Filing Date
Aug 31, 2015
Status
Granted And Under Opposition
Oct 1, 2021
Grant Date
Nov 3, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERAug 3, 2022AERAADMISSIBLE
ALFRED E TIEFENBACHERAug 3, 2022BARDEHLE PAGENBERG SLADMISSIBLE
GALENICUM HEALTH SLUAug 3, 2022GALENICUM HEALTH SLUADMISSIBLE
HOLLATZAug 3, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
KELTIEAug 3, 2022MOOREADMISSIBLE
QUIMICA SINTETICAAug 3, 2022AERAADMISSIBLE
QUIMICA SINTETICAAug 3, 2022BARDEHLE PAGENBERG SLADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5033252
DESCRIPTIONUS5052558
DESCRIPTIONUS5323907
DESCRIPTIONUS7214695
DESCRIPTIONUS8576985
INTERNATIONAL-SEARCH-REPORTUS7214695
INTERNATIONAL-SEARCH-REPORTWO2013038351
OPPOSITIONEP1587821
OPPOSITIONUS7214695
OPPOSITIONWO2004056315
OPPOSITIONWO2013038351
OPPOSITIONWO2019175263
OPPOSITIONWO2020232325
OPPOSITIONWO2021001858
OPPOSITIONWO2021152623

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "2.9.33. - Characterisation of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD)", Anonymous, European Pharmacopeia 7.0, (20090101), pages 301 - 305, XP055582946-
OPPOSITION- Anonymous, "2.9.33. - Characterisation of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD)", European Pharmacopeia 7.0, (20090101), pages 301 - 305, XP055582946-
OPPOSITION- Anonymous, "Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)", Pfizer’s, (20111116), pages 1 - 12, XP055951543-
OPPOSITION- Ema Chmp, "Vyndaqel - tafamidis meglumine", Assessment report EMEA/H/C/002294, (20110922), pages 1 - 85, XP055952004-
OPPOSITION- H.G. Brittain, Polymorphism in Pharmaceutical Solids, 2nd ed., Informa Healthcare , (20090101), pages 333 - 338, XP055587170-
OPPOSITION- H. RAZAVI et al., "Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation and mechanism of action", Angew. Chem. Int. Ed., (20030000), vol. 42, pages 2758 - 2761, XP055951500-
OPPOSITION- Jensen A., "PXRD Analysis of 6-carboxy-2(3,5-dichlrophenyl)-benzoxazole synthesised according to the procedufre of Angew. Chem. Int. Ed.", Pfizer - Material Science, (20190219), pages 1 - 6, XP055951996-
OPPOSITION- "Kapitel 7", BAUER-FROMMING-FUHRER, LEHRBUCH DER PHARMAZEUTISCHEN TECHNOLOGIE, Stuttgart, (20060000), pages 214 - 217, XP055951526-
OPPOSITION- Perfect H., "Synthesis of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole according to the procedure of Angew. Chem.", Pfizer, (20190219), pages 1 - 4, XP055951991-
OPPOSITION- Razavi H., Et Al., "Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation and mechanism of action", Angew. Chem. Int. Ed., (20030101), pages 2758 - 2761, Angew. Chem. Int. Ed., (20220815), XP055951500-
OPPOSITION- Razavi H., Et Al., "Supporting Information for Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation and mechanism of action", Angew. Chem. Int. Ed., (20030101), pages FP, S1 - S23, XP055951500-
OPPOSITION- "X-Ray Diffraction", H.G. Brittain, Polymorphism in Pharmaceutical Solids, Informa Healthcare , (20090101), pages 333 - 338, XP055587170-
OPPOSITION- ADDADI L ET AL, "Taking advantage of disorder: amorphous calcium carbonate and its roles in biomineralization", Advanced Materials, DE , (20030617), vol. 15, no. 12, doi:10.1002/adma.200300381, ISSN 0935-9648, pages 959 - 970, XP002460425
OPPOSITION- RAZAVI et al., "Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", Angew. Chem. Int. Ed., (20030000), vol. 42, no. 24, pages 2758 - 2761, XP002322019
OPPOSITION- RAZAVI H, et al, "Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", Angewandte Chemie International Edition, (20030101), vol. 42, doi:10.1002/anie.200351179, ISSN 1433-7851, pages 2758 - 2761, XP002322019
OPPOSITION- RAZAVI H, et al, "Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, evaluation, and Mechanism of Action", Angewandte Chemie International Edition, Verlag Chemie, (20030101), vol. 42, doi:10.1002/anie.200351179, ISSN 1433-7851, pages 2758 - 2761, XP002322019
OPPOSITION- Yu Lian, "Amorphous pharmaceutical solids: preparation, characterization and stabilization", Advanced Drug Delivery Reviews, (20010000), vol. 48, pages 27 - 42, XP009065056
OPPOSITION- Craig D, Royall Paul G, Kett Vicky L, Hopton Michelle L, "The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems", International Journal of Pharmaceutics, (19990000), vol. 179, pages 179 - 207, XP002274233
OPPOSITION- HANCOCK et al., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems", Journal of Pharmaceutical Sciences, (19970000), vol. 86, no. 1, pages 1 - 12, XP055274556
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, New York, (19950701), vol. 12, no. 7, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, Springer US, New York, New York, (19950701), vol. 12, no. 07, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
OPPOSITION- Stephen Byrn; Ralph Pfeiffer; Michael Ganey; Charles Hoiberg and Guirag Poochikian, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP055531015
OPPOSITION- Bulawa Christine E., Connelly Stephen, Devit Michael, Wang Lan, Weigel Charlotte, Fleming James A., Packman Jeff, Powers Evan T., Wiseman R. Luke, Foss Theodore R., Wilson Ian A., Kelly Jeffery W., Labaudinière Richard, "Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade", PNAS, (20120000), vol. 109, no. 24, pages 9629 - 9634, XP055679260
OPPOSITION- S. C. Penchala, S. Connelly, Y. Wang, M. S. Park, L. Zhao, A. Baranczak, I. Rappley, H. Vogel, M. Liedtke, R. M. Witteles, E. T. Powers, N. Reixach, W. K. Chan, I. A. Wilson, J. W. Kelly, I. A. Graef, M. M. Alhamadsheh, "AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin", Proceedings of the National Academy of Sciences, (20130611), vol. 110, no. 24, doi:10.1073/pnas.1300761110, ISSN 0027-8424, pages 9992 - 9997, XP055221811
OPPOSITION- IMAIZUMI H, NAMBU N, NAGAI T, "STABILITY AND SEVERAL PHYSICAL PROPERTIES OF AMORPHOUS AND CRYSTALLINE FORMS OF INDOMETHACIN", Chemical and Pharmaceutical Bulletin, JP , (19800101), vol. 28, no. 09, ISSN 0009-2363, pages 2565 - 2569, XP001206577

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents